Interdose control of beta-blockade and arterial blood pressure during chronic oral labetalol treatment.
1 The pharmacological and therapeutic effects of labetalol were investigated during an 8 h interdose period of chronic oral therapy in six patients with essential hypertension. 2 Peak plasma labetalol concentrations were observed 2 h after the morning oral dose, and subsequent decline was mono exponential. 3 Beta-adrenoceptor blockade paralleled the changes in labetalol concentration and was maximal 2 and 4 h after the oral dose. 4 Resting supine systolic BP rose significantly during the interdose period, but no change occurred in diastolic BP. 5 Ambulatory intra-arterial BP studies in a further six patients with essential hypertension controlled with labetalol did not confirm the increase in BP during an 8 h interdose period.
D000319:Adrenergic beta-Antagonists; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects*; D004334:Drug Administration Schedule; D004983:Ethanolamines / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007545:Isoproterenol / Q000097:blood / Q000627:therapeutic use; D007741:Labetalol / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D004983:Ethanolamines; D007545:Isoproterenol; D007741:Labetalol